company background image
6242

Li Kang Biomedical TPEX:6242 Stock Report

Last Price

NT$45.55

Market Cap

NT$1.1b

7D

-8.0%

1Y

23.9%

Updated

29 Sep, 2022

Data

Company Financials
6242 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance1/6
Financial Health6/6
Dividends3/6

6242 Stock Overview

Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drinks.

Li Kang Biomedical Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Li Kang Biomedical
Historical stock prices
Current Share PriceNT$45.55
52 Week HighNT$78.57
52 Week LowNT$35.71
Beta0.44
1 Month Change-5.99%
3 Month Change-2.99%
1 Year Change23.91%
3 Year Change19.42%
5 Year Change10.97%
Change since IPO-86.77%

Recent News & Updates

Shareholder Returns

6242TW Personal ProductsTW Market
7D-8.0%-8.2%-7.0%
1Y23.9%-8.5%-19.7%

Return vs Industry: 6242 exceeded the TW Personal Products industry which returned -8.5% over the past year.

Return vs Market: 6242 exceeded the TW Market which returned -19.7% over the past year.

Price Volatility

Is 6242's price volatile compared to industry and market?
6242 volatility
6242 Average Weekly Movement6.2%
Personal Products Industry Average Movement5.8%
Market Average Movement5.1%
10% most volatile stocks in TW Market8.3%
10% least volatile stocks in TW Market2.5%

Stable Share Price: 6242 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 6242's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1982123n/ahttps://www.likangbio.com

Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drinks. It also engages in management and consulting of tourism factory business; and offers telemarketing services. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd.

Li Kang Biomedical Fundamentals Summary

How do Li Kang Biomedical's earnings and revenue compare to its market cap?
6242 fundamental statistics
Market CapNT$1.06b
Earnings (TTM)NT$73.37m
Revenue (TTM)NT$498.34m

14.5x

P/E Ratio

2.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6242 income statement (TTM)
RevenueNT$498.34m
Cost of RevenueNT$209.43m
Gross ProfitNT$288.90m
Other ExpensesNT$215.53m
EarningsNT$73.37m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)3.15
Gross Margin57.97%
Net Profit Margin14.72%
Debt/Equity Ratio5.7%

How did 6242 perform over the long term?

See historical performance and comparison

Dividends

3.1%

Current Dividend Yield

45%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is 6242 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6242?

Other financial metrics that can be useful for relative valuation.

6242 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.8x
Enterprise Value/EBITDA9.2x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 6242's PE Ratio compare to its peers?

6242 PE Ratio vs Peers
The above table shows the PE ratio for 6242 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average17.5x
4732 NatureWise Biotech & Medicals
23.7xn/aNT$1.5b
6703 Shiny Brands Group
14.3xn/aNT$2.0b
1731 Maywufa
15xn/aNT$2.3b
8480 Taisun Int'l (Holding)
17.1xn/aNT$3.3b
6242 Li Kang Biomedical
14.5xn/aNT$1.1b

Price-To-Earnings vs Peers: 6242 is good value based on its Price-To-Earnings Ratio (14.5x) compared to the peer average (17.5x).


Price to Earnings Ratio vs Industry

How does 6242's PE Ratio compare vs other companies in the Asian Personal Products Industry?

Price-To-Earnings vs Industry: 6242 is good value based on its Price-To-Earnings Ratio (14.5x) compared to the Asian Personal Products industry average (25.5x)


Price to Earnings Ratio vs Fair Ratio

What is 6242's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6242 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 6242's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 6242 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6242 (NT$45.55) is trading below our estimate of fair value (NT$59.86)

Significantly Below Fair Value: 6242 is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Li Kang Biomedical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.9%

Forecasted Household industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Li Kang Biomedical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine whether Li Kang Biomedical is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.

Past Performance

How has Li Kang Biomedical performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-15.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6242 has high quality earnings.

Growing Profit Margin: 6242's current net profit margins (14.7%) are lower than last year (15.4%).


Past Earnings Growth Analysis

Earnings Trend: 6242's earnings have declined by 15.3% per year over the past 5 years.

Accelerating Growth: 6242's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 6242 had negative earnings growth (-7.4%) over the past year, making it difficult to compare to the Personal Products industry average (-11.6%).


Return on Equity

High ROE: 6242's Return on Equity (14.6%) is considered low.


Discover strong past performing companies

Financial Health

How is Li Kang Biomedical's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 6242's short term assets (NT$296.6M) exceed its short term liabilities (NT$156.8M).

Long Term Liabilities: 6242's short term assets (NT$296.6M) exceed its long term liabilities (NT$31.7M).


Debt to Equity History and Analysis

Debt Level: 6242 has more cash than its total debt.

Reducing Debt: 6242's debt to equity ratio has reduced from 21.3% to 5.7% over the past 5 years.

Debt Coverage: 6242's debt is well covered by operating cash flow (291.6%).

Interest Coverage: 6242 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Li Kang Biomedical current dividend yield, its reliability and sustainability?

Dividend Score

3/6

Dividend Score 3/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


3.14%

Current Dividend Yield

Dividend Yield vs Market

Li Kang Biomedical Dividend Yield vs Market
How does Li Kang Biomedical dividend yield compare to the market?
SegmentDividend Yield
Company (Li Kang Biomedical)3.1%
Market Bottom 25% (TW)2.6%
Market Top 25% (TW)7.1%
Industry Average (Personal Products)3.9%
Analyst forecast in 3 Years (Li Kang Biomedical)n/a

Notable Dividend: 6242's dividend (3.14%) is higher than the bottom 25% of dividend payers in the TW market (2.63%).

High Dividend: 6242's dividend (3.14%) is low compared to the top 25% of dividend payers in the TW market (7.14%).


Stability and Growth of Payments

Stable Dividend: 6242 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 6242's dividend payments have increased, but the company has only paid a dividend for 7 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (45.4%), 6242's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (41.1%), 6242's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Li Kang Biomedical has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 6242?
Owner TypeNumber of SharesOwnership Percentage

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Company Information

Li Kang Biomedical Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Li Kang Biomedical Co., Ltd.
  • Ticker: 6242
  • Exchange: TPEX
  • Founded: 1982
  • Industry: Personal Products
  • Sector: Household
  • Implied Market Cap: NT$1.062b
  • Shares outstanding: 23.31m
  • Website: https://www.likangbio.com

Number of Employees


Location

  • Li Kang Biomedical Co., Ltd.
  • No. 29, Huangong Road
  • Yongkang District
  • Tainan City
  • 710
  • Taiwan


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
6242TPEX (Taipei Exchange)YesCommon StockTWTWDApr 2003

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/29 00:00
End of Day Share Price2022/09/28 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.